This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Oxygen Biotherapeutics Reports Second Quarter FY2011 Financial Results

Six Month Results

Net revenue for the six months ended October 31, 2010 was $32,236 compared to total revenue of $6,561 for the same period in fiscal year 2010. This was primarily due to DERMACYTE product sales.

For the six-month period ending October 31, 2010 the company had total operating expenses of $5,112,174 compared to $4,883,586 for the same period in 2009. The increase is primarily due to costs incurred for compensation, clinical trials, development and manufacture of Oxycyte, a reduction in costs incurred for stock-based compensation, and marketing and sales expenses for DERMACYTE products.

The Company reported a net loss of $5,054,236, or $0.22 per share for the six month period ended October 31, 2010, compared to a net loss of $4,985,890, or $0.28 per share for the same period in 2009.

As of October 31, 2010, the Company had cash and cash equivalents totaling $837,167, up from $632,706 at April 30, 2010.

Conference Call

Management will host a conference call on Friday, December 10, 2010 at 11 a.m. EST. To access the live teleconference dial (866) 825-3209 (U.S. and Canada) or (617) 213-8061 (international.) The participant passcode is 81091554. A live webcast will be available on our web site .

A replay of the webcast will be available on the Oxygen Biotherapeutics website, or by phone for a limited time. To access the replay by phone, call (888) 286-8010 (U.S. and Canada) or (617) 801-6888 (international) for a limited time. The passcode for the replay is 25705024.
(a development stage enterprise)
  October 31, 2010 (Unaudited) April 30, 2010
Current assets    
Cash and cash equivalents $ 837,167 $ 632,706
Accounts receivable 22,144 72,055
Inventory 443,044 535,090
Prepaid expenses 228,118 249,780
Other current assets 81,247 695,195
Total current assets 1,611,720 2,184,826
Property and equipment, net 439,666 383,959
Intangible assets, net 918,567 907,710
Other assets 123,877 52,651
Total assets $ 3,093,830 $ 3,529,146
Current liabilities    
Accounts payable $1,076,425 $499,044
Accrued liabilities 381,928 843,903
Notes payable 7,195 56,394
Total current liabilities 1,465,548 1,399,341
Long-term portion of convertible debt, net  --  2,767
Total liabilities 1,465,548 1,402,108
Stockholders' equity    
Preferred stock, undesignated, authorized 10,000,000 shares; none issued or outstanding    
Common stock, par value $.0001 per share; authorized 400,000,000 shares; issued and outstanding 23,386,460 and 21,457,265, respectively 2,339 2,146
Stock subscription receivable  --  500,000
Additional paid-in capital 88,147,757 83,092,470
Deficit accumulated during the development stage (86,521,814) (81,467,578)
Total stockholders' equity 1,628,282 2,127,038
Total liabilities and stockholders' equity $ 3,093,830 $ 3,529,146
(a development stage enterprise)
  Three months ended October 31, Six months ended October 31,
  2010 2009 2010 2009
  (Unaudited) (Unaudited) (Unaudited) (Unaudited)
Revenue $ 36,083 $ 6,561 $ 42,981 $ 6,561
Cost of sales 8,957  --  10,745  -- 
Net Revenue 27,126 6,561 32,236 6,561
Operating Expenses        
Selling, general, and administrative 1,511,214 2,185,917 3,394,282 3,937,196
Research and development 572,649 407,134 1,717,892 946,390
Loss on impairment of long-lived assets  --   --   --   -- 
Total operating expenses 2,083,863 2,593,051 5,112,174 4,883,586
Net operating loss 2,056,737 2,586,490 5,079,938 4,877,025
Interest expense 5,383 23,274 6,589 150,699
Loss on extinguishment of debt  --   --   --   -- 
Other income (10,183) (20,552) (32,291) (41,834)
Net loss $ 2,051,937 $ 2,589,212 $ 5,054,236 $ 4,985,890
Net loss per share, basic and diluted $ (0.09) $ (0.13) $ (0.22) $ (0.28)
Weighted average number of common shares outstanding, basic and diluted 23,387,979 19,603,257 23,301,844 18,002,270

About Oxygen Biotherapeutics, Inc.

Headquartered in Durham, NC, Oxygen Biotherapeutics, Inc. is developing medical and cosmetic products that efficiently deliver oxygen to tissues in the body. The company has developed a proprietary perfluorocarbon (PFC) therapeutic oxygen carrier called Oxycyte that is being formulated for both intravenous and topical delivery. Potential indications include traumatic brain injury, decompression sickness, wounds and pruritis. This year, the company launched its DERMACYTE ® line of oxygen-rich skin care products. More information is available at or .

The Oxygen Biotherapeutics, Inc. logo is available at

Caution Regarding Forward-Looking Statements

This news release contains certain forward-looking statements by the company that involve risks and uncertainties and reflect the company's judgment as of the date of this release. These statements include the expansion of development of the Oxycyte and DERMACYTE product lines and the timing of the introduction of those new products. The forward-looking statements are subject to a number of risks and uncertainties including matters beyond the company's control that could lead to delays in new product introductions and customer acceptance of these new products, and other risks and uncertainties as described in our filings with the Securities and Exchange Commission, including in the current reports on Form 10-Q and Form-10K. The company disclaims any intent or obligation to update these forward-looking statements beyond the date of this release. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
CONTACT:  Oxygen Biotherapeutics, Inc. 
          Corporate Communications & Investor Relations 
          Ellen Corliss, Vice President
          (919) 855-2112

Oxygen Biotherapeutics, Inc. logo

2 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
AAPL $95.18 1.64%
FB $117.43 -0.96%
GOOG $692.36 -0.84%
TSLA $232.32 -3.92%
YHOO $36.01 -1.42%


Chart of I:DJI
DOW 17,750.91 -140.25 -0.78%
S&P 500 2,063.37 -18.06 -0.87%
NASDAQ 4,763.2240 -54.37 -1.13%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs